CONVALESCENT PLASMA TRANSFUSION FOR THE TREATMENT CRIMEAN-CONGO HEMORRHAGIC FEVER (REVIEW)

Vestnik ◽  
2021 ◽  
pp. 319-322
Author(s):  
Г.Н. Абуова ◽  
Т.В. Полукчи ◽  
Ф.А. Бердалиева ◽  
Д.С. Алиев ◽  
Э.Ю. Алиев
Keyword(s):  
Effective Treatment ◽  
Clinical Symptoms ◽  
Hemorrhagic Fever ◽  
Treatment Method ◽  
Limited Data ◽  
Plasma Transfusion ◽  
Plasma Therapy ◽  
Antibacterial Drugs ◽  
Crimean Congo Hemorrhagic Fever

Проведен анализ литературных данных о применении плазменной терапии при лечении Конго-Крымской геморрагической лихорадки в мире. Данный обзор проведен для оценки эффективности плазменной терапии у пациентов с Конго-Крымской геморрагической лихорадкой на основе научных данных, опубликованных до настоящего времени. В последние годы отмечается определенный интерес к изучению плазменной терапии при лечении пациентов с Конго-Крымской геморрагической лихорадкой, хотя в литературе имеются лишь ограниченные данные по эффективности иммунотерапии и применения рибавирина при Конго-Крымской геморрагической лихорадке, при этом действенность рибавирина остается еще не доказанной. Однако можно предположить, что помимо противовирусных препаратов, применение плазменной терапии у больных с Конго-Крымской геморрагической лихорадкой может быть эффективным способом лечения, улучшающим клинические симптомы у пациентов, прогноз и снижающим смертность. The analysis of the literature data on the using of plasma therapy in the treatment of Congo-Crimean hemorrhagic fever was carried out. This review was conducted to evaluate the effectiveness of plasma therapy in patients with Congo-Crimean hemorrhagic fever on the basis of publications published so far. In recent years, there has been some interest in studying plasma therapy in the treatment of patients with Congo-Crimean hemorrhagic fever, although there are only limited data in the literature on the effectiveness of immunotherapy and the use of ribavirin in therapy, while the effectiveness of ribavirin remains not yet proven. However, it can be assumed that in addition to antiviral and antibacterial drugs, the use of plasma therapy in patients with Congo-Crimean hemorrhagic fever can be an effective treatment method that improves clinical symptoms in patients and reduces mortality.

scholarly journals Mice Orally Immunized with a Transgenic Plant Expressing the Glycoprotein of Crimean-Congo Hemorrhagic Fever Virus

2011 ◽  
Vol 18 (12) ◽  
pp. 2031-2037 ◽  
Author(s):  
S. M. Ghiasi ◽  
A. H. Salmanian ◽  
S. Chinikar ◽  
S. Zakeri
Keyword(s):  
Transgenic Plants ◽  
Transgenic Plant ◽  
Disease Transmission ◽  
Clinical Symptoms ◽  
Hemorrhagic Fever ◽  
Oral Immunization ◽  
Negative Control ◽  
Significant Rise ◽  
Knockout Mouse Model ◽  
Crimean Congo Hemorrhagic Fever

ABSTRACTWhile Crimean-Congo hemorrhagic fever (CCHF) has a high mortality rate in humans, the associated virus (CCHFV) does not induce clinical symptoms in animals, but animals play an important role in disease transmission to humans. Our aim in this study was to examine the immunogenicity of the CCHFV glycoprotein when expressed in the root and leaf of transgenic plants via hairy roots and stable transformation of tobacco plants, respectively. After confirmatory analyses of transgenic plant lines and quantification of the expressed glycoprotein, mice were either fed with the transgenic leaves or roots, fed the transgenic plant material and injected subcutaneously with the plant-made CCHFV glycoprotein (fed/boosted), vaccinated with an attenuated CCHF vaccine (positive control), or received no treatment (negative control). All immunized groups had a consistent rise in anti-glycoprotein IgG and IgA antibodies in their serum and feces, respectively. The mice in the fed/boosted group showed a significant rise in specific IgG antibodies after a single boost. Our results imply that oral immunization of animals with edible materials from transgenic plants is feasible, and further assessments are under way. In addition, while the study of CCHF is challenging, our protocol should be further used to study CCHFV infection in the knockout mouse model and virus neutralization assays in biosafety level 4 laboratories.

scholarly journals Convalescent Plasma Therapy in COVID 19 an Indian Scenario: Comprehensive Review

2021 ◽  
pp. 453-465
Author(s):  
Shruti Vimal ◽  
Pratiksha Naval ◽  
Manoj Sawadker ◽  
Pallavi Bhomia ◽  
Neha Jadhav ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Neutralizing Antibodies ◽  
Clinical Symptoms ◽  
Scientific Data ◽  
Plasma Transfusion ◽  
Eligibility Criteria ◽  
Plasma Therapy ◽  
Comprehensive Review ◽  
Proof Of Efficacy ◽  
Indian Scenario

The recent pandemic due to Corona virus more popularly known as COVID 19 has reassessed the usefulness of historic convalescent plasma transfusion. (CPT) The CPT is one of the promising therapies in the current pandemic situation. This review was conducted to evaluate the effectiveness of CPT therapy in COVID 19 patients based on the publications reported till date. PubMed, EMBASE and Medline databases were screened up to 30 April 2021. All the records were screened as per the protocol eligibility criteria.  The main features of the studies reviewed were, convalescent plasma can reduce mortality in severely ill patients, an increase in neutralizing antibodies titre and disappearance of SARS CoV 2 RNA was observed in all the patients on CPT therapy and over all a beneficial effect on clinical symptoms after administration of CP.  Based on the review findings and the limited scientific data, CPT therapy in COVID 19 patients appear safe, clinically effective and reduces mortality. However, the need of a multicentre clinical trials, unequivocal proof of efficacy, effectiveness and the need for the standardisation of the CPT needs to be addressed immediately for the full utilisation of potential of CPT.

scholarly journals Investigating dizziness symptom in adult cases with Crimean-Congo hemorrhagic fever using various scales

2021 ◽  
Vol 37 (1) ◽  
Author(s):  
Adem Bora ◽  
Seyit Ali Büyüktuna ◽  
Kasım Durmuş ◽  
Berat Baturay Demirkıran ◽  
Yasin Aslan ◽  
...  
Keyword(s):  
Activities Of Daily Living ◽  
Disease Severity ◽  
Daily Living ◽  
Clinical Symptoms ◽  
Hemorrhagic Fever ◽  
The Self ◽  
Multicenter Studies ◽  
Pathophysiological Mechanisms ◽  
Crimean Congo Hemorrhagic Fever ◽  
Vestibular Symptoms

Abstract Background This study was to investigate the frequency of self-reported dizziness symptom in cases with Crimean-Congo hemorrhagic fever (CCHF) and the severity of dizziness, if any, by using various scales. The frequency and severity of the self-reported dizziness symptom of CCHF patients, level of disability caused by dizziness, and to what extent vestibular symptoms affected activities of daily living were assessed by various scales. The frequency and severity of the self-reported dizziness symptom of CCHF patients, level of disability caused by dizziness, and to what extent vestibular symptoms affected activities of daily living were assessed by various scales. Results The frequency of dizziness in CCHF cases included in the study was 11.11% and all the cases were involved in the mild category in terms of disease severity. When the results of the scales applied to all of the cases were evaluated in general, it was seen that there was no vertigo or dizziness. Conclusion According to the results of the present study, we consider that multicenter studies with large series investigating pathophysiological mechanisms underlying these clinical symptoms are needed in order to evaluate dizziness symptom and to make definitive interpretations in CCHF disease.

scholarly journals Crimean-Congo hemorrhagic fever virus antibody prevalence in Mauritanian livestock (cattle, goats, sheep and camels) is stratified by the animal’s age

2021 ◽  
Vol 15 (4) ◽  
pp. e0009228
Author(s):  
Ansgar Schulz ◽  
Yahya Barry ◽  
Franziska Stoek ◽  
Aliou Ba ◽  
Jana Schulz ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Small Ruminants ◽  
Hemorrhagic Fever ◽  
Immunofluorescence Assay ◽  
Fever Virus ◽  
Crimean Congo Hemorrhagic Fever ◽  
Prevalence Studies ◽  
Hemorrhagic Fever Virus ◽  
Generalized Linear Mixed Effects ◽  
The Impact

Crimean-Congo hemorrhagic fever virus (CCHFV) is one of the most widespread zoonotic arthropod-borne viruses in many parts of Africa, Europe and Asia. It belongs to the family of Nairoviridae in the genus of Orthonairovirus. The main reservoir and vector are ticks of the genus Hyalomma. Livestock animals (such as cattle, small ruminants and camels) develop a viremias lasting up to two weeks with absence of clinical symptoms, followed by seroconversion. This study was carried out to assess risk factors that affect seroprevalence rates in different species. In total, 928 livestock animal samples (cattle = 201; sheep = 247; goats = 233; camels = 247) from 11 out of 13 regions in Mauritania were assayed for CCHFV-specific immunoglobulin G (IgG) antibodies using enzyme-linked immunosorbent assays (ELISA) (including a novel indirect camel-IgG-specific CCHFV ELISA). Inconclusive results were resolved by an immunofluorescence assay (IFA). A generalized linear mixed-effects model (GLMM) was used to draw conclusions about the impact of certain factors (age, species, sex and region) which might have influenced the CCHFV antibody status of surveyed animals. In goats and sheep, about 15% of the animals were seropositive, whereas in cattle (69%) and camels (81%), the prevalence rate was significantly higher. On average, cattle and camels were up to twice to four times older than small ruminants. Interestingly, the seroprevalence in all species was directly linked to the age of the animals, i.e. older animals had significantly higher seroprevalence rates than younger animals. The highest CCHFV seroprevalence in Mauritania was found in camels and cattle, followed by small ruminants. The large proportion of positive animals in cattle and camels might be explained by the high ages of the animals. Future CCHFV prevalence studies should at least consider the age of surveyed animals in order to avoid misinterpretations.

scholarly journals Modern aspects of differential diagnosis of the Crimean-Congo hemorrhagic fever

2014 ◽  
Vol 95 (5) ◽  
pp. 748-751
Author(s):  
L P Cherenova ◽  
H M Galimzyanov ◽  
V V Vasilkova ◽  
I V Cherenov
Keyword(s):  
Differential Diagnosis ◽  
Clinical Symptoms ◽  
Q Fever ◽  
Laboratory Data ◽  
Hemorrhagic Fever ◽  
Epidemiological Data ◽  
Diagnostic Features ◽  
Crimean Congo Hemorrhagic Fever ◽  
Abdominal Bleeding ◽  
Pathogenetic Therapy

Aim. To lay down criteria for the differential diagnosis of Crimean-Congo hemorrhagic fever with a number of natural focal diseases prevalent in the Astrakhan region. Methods. A retrospective analysis of clinical, epidemiological and laboratory data of patients with Crimean-Congo hemorrhagic fever (74 cases), Astrakhan rickettsial fever (75), Q fever (75) and leptospirosis (25) was carried out in 2000-2013. Results. The basic clinical symptoms characteristic of the Crimean-Congo hemorrhagic fever for the differential diagnosis of Astrakhan rickettsial fever, Q fever and leptospirosis were distinguished. The early diagnosis of Crimean-Congo hemorrhagic fever was based on the epidemiological data taking into account spring-summer seasonality of the disease, patient’s visits to countryside, contact with animals, and data about tick bites and contact with ticks. Timely prescription of adequate antiviral and pathogenetic therapy helped to reduce the rate of severe forms and mortality from Crimean-Congo hemorrhagic fever. Conclusion. Differential diagnostic features of Crimean-Congo hemorrhagic fever were: the presence of the primary affect on the site of the tick bite, high body temperature, two-wave fever, significant signs of intoxication, the relative and absolute bradycardia, hemorrhagic rash, abdominal bleeding, changes of peripheral blood - leukopenia and thrombocytopenia.

scholarly journals Kırım-Kongo Kanamalı Ateşi: 16 Olgunun Klinik Özelliklerinin ve Laboratuvar Bulgularının Retrospektif Değerlendirilmesi

2020 ◽  
Vol 25 (4) ◽  
pp. 544-548
Author(s):  
Deniz Akyol ◽  
Esra Erdem Kıvrak ◽  
Hüseyin Aytaç Erdem ◽  
Hüsnü Pullukçu ◽  
Oğuz Reşat Sipahi ◽  
...  
Keyword(s):  
Blood Count ◽  
Blood Product ◽  
Clinical Symptoms ◽  
Hemorrhagic Fever ◽  
Test Results ◽  
Blood Products ◽  
Important Public Health ◽  
Crimean Congo Hemorrhagic Fever ◽  
Contact Isolation ◽  
History Of

Introduction: Crimean-Congo Hemorrhagic Fever (CCHF) is a zoonotic disease frequently transmitted by tick bite and accompanied by fever and bleeding. It may cause important public health problems. Besides clinical symptoms and epidemiological history, blood count and biochemical test results are the first clues for CCHF. In this study, we aimed to retrospectively evaluate 16 patients who were followed and treated due to CCHF in our hospital. Materials and Methods: The patients who were followed up and treated with CCHF between 2009-2019 in our clinic were evaluated retrospectively in terms of demographic characteristics, presenting complaints, presence of tick history, laboratory parameters, necessity of blood products replacement, hospitalization periods, ribavirin treatment and one-month survival. Results: Sixteen patients [ten females, six males, mean age 50.37 ± 18.01 (min: 18-max: 79)] with the diagnosis of CCHF were included into the study. Presenting complaints were fever (16/16, 100%), fatigue (16/16, 100%), bleeding (9/16, 56.2%), petechial rash (7/16, 43.7%). nausea and vomiting (6/16, 37.5%). There was a history of tick contact in 14 cases (87.5%) but not in two cases. Supportive treatment was applied to all cases, and droplet and contact isolation were applied. Blood product replacement was performed in five patients (31.2%), and ribavirin was administered in nine patients (56.2%). Mortality rate was 6.3% (1/16). Conclusion: Crimean-Congo Hemorrhagic Fever is an endemic disease in our country. Especially in spring and summer months, patients with fever and cytopenia on hemogram should be questioned, and tick contact should be sought.

Sign in / Sign up

Export Citation Format

Share Document